Bio-Techne (TECH) 10-Q 7 May 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2019	May 01, 2019
Document Information [Line Items]
Entity Registrant Name	BIO-TECHNE Corp
Entity Central Index Key	0000842023
Trading Symbol	tech
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		37,766,000
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Net sales	$ 184,861	$ 163,973	$ 522,341	$ 462,739
Cost of sales	60,251	53,712	177,110	152,777
Gross margin	124,610	110,261	345,231	309,962
Operating expenses:
Selling, general and administrative	64,968	53,285	195,622	175,349
Research and development	15,552	13,892	46,154	41,350
Total operating expenses	80,520	67,177	241,776	216,699
Operating income	44,090	43,084	103,455	93,263
Other income (expense)	5,787	(18,102)	(14,226)	(23,581)
Earnings before income taxes	49,877	24,982	89,229	69,682
Income tax expense (benefit)	5,223	5,244	9,617	(14,767)
Net earnings	44,654	19,738	79,612	84,449
Other comprehensive income:
Foreign currency translation gain (loss)	5,232	2,297	(4,368)	10,787
Unrealized gain (loss) on derivative instruments - cash flow hedges	(1,854)		(5,769)
Unrealized gain (loss) on available-for-sale investments		38,659		22,286
Other comprehensive income (loss)	3,378	40,956	(10,137)	33,073
Comprehensive income	$ 48,032	$ 60,694	$ 69,475	$ 117,522
Earnings per share:
Basic (in dollars per share)	$ 1.18	$ 0.53	$ 2.11	$ 2.25
Diluted (in dollars per share)	1.15	0.52	2.05	2.22
Cash dividends per common share: (in dollars per share)	$ 0.32	$ 0.32	$ 0.96	$ 0.96
Weighted average common shares outstanding:
Basic (in shares)	37,772	37,503	37,745	37,450
Diluted (in shares)	38,861	38,142	38,813	37,933

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Current assets:
Cash and cash equivalents	$ 95,561	$ 121,990
Short-term available-for-sale investments	83,229	59,764
Accounts receivable, less allowance for doubtful accounts of $1,037 and $839, respectively	133,927	120,296
Inventories	93,839	85,648
Other current assets	16,877	10,668
Total current assets	423,433	398,366
Property and equipment, net	145,319	145,348
Goodwill	719,608	597,890
Intangible assets, net	579,142	446,332
Other assets	5,116	5,266
Total assets	1,872,618	1,593,202
Current liabilities:
Trade accounts payable	14,898	18,452
Salaries, wages and related accruals	23,523	23,710
Accrued expenses	28,296	20,361
Contract liabilities	10,112	8,109
Income taxes payable	5,318	8,878
Current portion of contingent consideration payable	3,400
Current portion of long-term debt obligations	12,500
Total current liabilities	98,047	79,510
Deferred income taxes	96,844	86,293
Long-term debt obligations, net of deferred financing costs of $360 and $0 respectively	509,765	339,000
Long-term contingent consideration payable	2,200
Other long-term liabilities	19,496	9,338
Shareholders' equity:
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 37,813,367 and 37,607,500, respectively	378	376
Additional paid-in capital	297,748	246,568
Retained earnings	927,773	876,931
Accumulated other comprehensive loss	(79,633)	(44,814)
Total shareholders' equity	1,146,266	1,079,061
Total liabilities and shareholders’ equity	$ 1,872,618	$ 1,593,202

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Accounts receivable, allowance for doubtful accounts	$ 1,037	$ 839
Deferred financing costs	$ 360	$ 0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	37,813,367	37,607,500
Common stock, shares outstanding (in shares)	37,813,367	37,607,500

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net earnings	$ 79,612	$ 84,449
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	58,252	47,311
Costs recognized on sale of acquired inventory	2,804	2,013
Deferred income taxes	(11,114)	(48,030)
Stock-based compensation expense	24,151	13,587
Fair value adjustment to contingent consideration payable	(1,100)	20,100
Payments of contingent consideration		(26,200)
Impairment of investment		16,226
Fair value adjustment on available for sale investments	(2,907)
Other operating activity	2,255	1,664
Change in operating assets and operating liabilities, net of acquisition:
Accounts receivable	(13,136)	9,399
Inventories	(11,550)	(11,576)
Prepaid expenses	(1,000)	858
Trade accounts payable and accrued expenses	7,977	1,665
Salaries, wages and related accruals	(102)	(4,159)
Income taxes payable	(8,469)	(1,779)
Net cash provided by operating activities	125,673	105,528
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisitions, net of cash acquired	(272,286)	(65,066)
Proceeds from maturities of available-for-sale investments	17,215	6,563
Purchases of available-for-sale investments	(37,693)	(3,061)
Purchases of property and equipment	(13,719)	(15,116)
Net cash used in investing activities	(306,483)	(76,680)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash dividends	(36,237)	(35,941)
Proceeds from stock option exercises	27,029	13,724
Re-purchases of common stock	(15,405)
Borrowings under credit agreement	580,000	55,000
Payments on credit agreement	(396,375)	(6,000)
Payments of contingent consideration		(58,800)
Other financing	(4,731)	(4,339)
Net cash provided by (used in) financing activities	154,281	(36,356)
Effect of exchange rate changes on cash and cash equivalents	99	2,504
Net increase (decrease) in cash and cash equivalents	(26,429)	(5,004)
Cash and cash equivalents at beginning of period	121,990	91,612
Cash and cash equivalents at end of period	95,561	86,608
Supplemental disclosure of cash flow information:
Cash paid for interest	16,110	6,877
Cash paid for income taxes	$ 26,637	$ 31,103

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	Note 1. Basis of Presentation and Summary of Significant Accounting Policies: The interim consolidated financial statements of Bio-Techne Corporation and subsidiaries, (the Company) presented here have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10 10 X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2018, 10 2018. 10 2018. Effective in the first 2019, not 2019. five two ● “Diagnostics and Genomics” will consist of the ACD division, the Diagnostics division, as well as the ExosomeDx acquisition. As part of the realignment, ACD will now be referred to as the Genomics division. ● “Protein Sciences” will consist of the Core Biotechnology division and the Protein Platforms division. As part of the realignment, Protein Platforms will now be referred to as the Analytical Solutions Division (ASD) and Core Biotechnology will now be referred to as the Reagent Solutions Division (RSD). Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, Revenue from Contracts with Customers 606 606 On July 1, 2018, 606 July 1, 2018 606, not 605, Revenue Recognition The Company recorded a net increase to beginning retained earnings of $98,000 July 1, 2018 606. 606 not nine March 31, 2019 not 2 606. In January 2016, No. 2016 01 Recognition and Measurement of Financial Assets and Financial Liabilities no 2016 01 July 1, 2018 $54.3 $35.4 $8.3 $27.1 2019. 2016 01, July 1, 2018 orded a gain in other (expense) income of $12.3 $2.9 nine March 31, 2019 2016 01 In February 2018, No. 2018 02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income 2017. December 15, 2018, July 1, 2019. 2018 02 July 1, 2018. $2.4 2018 02 2016 01 The following table presents a summary of cumulative effect adjustments to retained earnings due to the adoption of new accounting standards on July 1, 2018 Cumulative Effect Adjustments to Retained Earnings on July 1, 2018 Increase / (Decrease) Cumulative effect adjustment to retained earnings due to the adoption of the following new accounting standards: ASU 2014-09 $ 98 ASU 2016-01 27,053 ASU 2018-02 (2,371 ) Net cumulative effect adjustments to retained earnings on July 1, 2018 due to the adoption of new accounting standards $ 24,780 In January 2017, No. 2017 01, Clarifying the Definition of a Business July 1, 2018, In August 2017, No. 2017 - 12, Targeted Improvements to Accounting for Hedging Activities December 15, 2018, July 1, 2019. 2017 12 October 1, 2018, 5. not Pronouncements Issued But Not In February 2016, 2016 02, Leases (Topic 842 December 15, 2018, July 1, 2019. Leases (Topic 842 ASU No. 2018 10 ASU 2019 01 ASU 2018 11 not 2018 11 Leases (Topic 842 not In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 ), Measurement of Credit Losses on Financial Instruments December 15, 2019, July 1, 2020. may December 15, 2018. 2016 13 In August 2018, No. 2018 15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract not December 15, 2019, July 1, 2020 may first 2018 15

Note 2 - Revenue Recognition

Note 2 - Revenue Recognition	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 2. Revenue Recognition: Consumables revenues consist of single-use products and are recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. The vast majority of service revenues consist of extended warranty contracts, post contract support (“PCS”), and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no not not not not not third third The Company has elected the exemption to not one not March 31, 2019. Contracts with customers that contain instruments may Payment terms for shipments to end-users are generally net 30 may 30 90 Contract assets include revenues recognized in advance of billings. Contract assets are included within other current assets in the accompanying balance sheet as the amount of time expected to lapse until the company's right to consideration becomes unconditional is less than one one March 31, 2019 not Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of March 31, 2019 June 30, 2018 11.5 $9.3 June 30, 2018 nine March 31, 2019 $0.9 $6.5 one Any claims for credit or return of goods must be made within 10 not Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We have elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized. The following tables present our disaggregated revenue for the periods presented. Revenue by type is as follows: Quarter Ended March 31 , Nine Months Ended March 31, 201 9 201 8 201 9 201 8 Consumables $ 153,783 $ 139,416 $ 429,340 385,164 Instruments 16,104 13,197 51,116 44,047 Services 9,565 8,362 27,027 25,400 Total product and services revenue, net 179,452 160,975 $ 507,483 454,611 Royalty revenues 5,409 2,998 14,858 8,128 Total revenues, net $ 184,861 $ 163,973 $ 522,341 462,739 Revenue by geography is as follows: Quarter Ended March 31, Nine Months Ended March 31, 201 9 201 8 201 9 201 8 United States $ 98,228 $ 86,447 $ 281,585 $ 246,857 EMEA, excluding United Kingdom 42,339 39,318 116,018 107,082 United Kingdom 10,737 9,164 26,703 24,276 APAC, excluding Greater China 14,943 13,107 39,990 36,439 Greater China 12,993 11,097 42,727 35,006 Rest of World 5,621 4,840 15,318 13,079 Total revenues, net $ 184,861 $ 163,973 $ 522,341 $ 462,739

Note 3 - Selected Balance Sheet

Note 3 - Selected Balance Sheet Data	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 3 . Selected Balance Sheet Data: Inventories: Inventories consist of (in thousands): March 31, 201 9 June 30, 2018 Raw materials $ 37,176 $ 30,956 Finished goods 56,663 54,692 Inventories, net $ 93,839 $ 85,648 Property and Equipment: Property and equipment consist of (in thousands): March 31, June 30, 201 9 2018 Land $ 7,065 $ 7,065 Buildings and improvements 172,826 170,110 Machinery and equipment 117,105 107,625 Property and equipment, cost 296,996 284,800 Accumulated depreciation and amortization (151,677 ) (139,452 ) Property and equipment, net $ 145,319 $ 145,348 Intangible Assets: Intangible assets consist of (in thousands): March 31, June 30, 201 9 2018 Developed technology $ 422,039 $ 305,303 Trade names 147,340 89,608 Customer relationships 212,996 212,228 Patents 1,981 1,401 Intangible assets 784,356 608,540 Accumulated amortization (205,214 ) (162,208 ) Intangible assets, net $ 579,142 $ 446,332 Changes to the carrying amount of net intangible assets for the nine March 31, 2019 Beginning balance $ 446,332 Acquisitions 177,500 Other additions 558 Amortization expense (43,797 ) Currency translation (1,451 ) Ending balance $ 579,142 The estimated future amortization expense for intangible assets as of March 31, 2019 2019 (remainder) $ 14,868 2020 58,873 2021 58,518 2022 56,822 2023 54,942 Thereafter 335,119 Total $ 579,142 Goodwill: Changes to the carrying amount of goodwill for the nine March 31, 2019 Protein Sciences Diagnostics and Genomics Total Beginning balance $ 347,918 $ 249,972 $ 597,890 Acquisitions (Note 4) 13,582 110,066 123,648 Currency translation (1,821 ) (108 ) (1,930 ) Ending balance $ 359,679 $ 359,929 $ 719,608 We evaluate the carrying value of goodwill in the fourth fourth 2018. June 30, 2018. During the quarter ended March 31, 2019, No nine March 31, 2019. no 350 July 1, 2002.

Note 4 - Acquisitions

Note 4 - Acquisitions	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Business Combination Disclosure [Text Block]	Note 4 . Acquisitions: We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and the results of operations of each acquired business are included in our Condensed Consolidated Statement of Earnings and Comprehensive Income from their respective dates of acquisition. Acquisition costs are recorded in selling, general and administrative expenses as incurred. Quad Technologies On July 2, 2018, $20.5 $51.0 not first 2019. Certain estimated fair values are not fourth 2019 Preliminary Allocation at Acquisition Date Adjustments to Fair Value Adjusted Preliminary Allocation at March 31, 201 9 Current assets, net of cash $ 36 $ - $ 36 Equipment and other long-term assets 284 - 284 Intangible assets: Developed technology 20,000 (7,800 ) 12,200 Goodwill 9,790 3,792 13,582 Total assets acquired 30,110 (4,008 ) 26,102 Liabilities 765 (469 ) 296 Deferred income taxes, net 3,741 (3,296 ) 445 Net assets acquired $ 25,604 $ (243 ) $ 25,361 Cash paid, net of cash acquired $ 20,404 $ 57 $ 20,461 Fair value of contingent consideration 5,200 (300 ) 4,900 Net assets acquired $ 25,604 $ (243 ) $ 25,361 As summarized in the table, there were adjustments totaling $3.8 Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology was estimated based on management's forecasted cash inflows and outflows using a multi-period excess earnings method to calculate the fair value of assets purchased. The preliminary amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The preliminary amortization periods for intangible assets acquired in fiscal 2019 14 not Exosome Diagnostics On August 1, 2018, $251.8 $325.0 ● Up to $250 2020 $45 $58 ● Up to $45 2022 $54 $70 ● Up to $30 2022 $150 $190 The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company’s product portfolio and the expected revenue growth from increased market penetration. The goodwill is not first 2019. Certain estimated fair values are not fourth 2019 Preliminary Allocation at Acquisition Date Adjustments to Fair Value Adjusted Preliminary Allocation at March 31, 201 9 Current assets, net of cash $ 5,118 $ (2,554 ) $ 2,564 Equipment and other long-term assets 2,212 - 2,212 Intangible assets: Developed technology 180,000 (75,000 ) 105,000 Trade Name - 58,000 58,000 Customer Relationships - 2,300 2,300 Goodwill 96,592 13,474 110,066 Total assets acquired 283,922 (3,780 ) 280,142 Liabilities 2,624 210 2,834 Deferred income taxes, net 27,673 (3,990 ) 23,683 Net assets acquired $ 253,625 $ - $ 253,625 Cash paid, net of cash acquired $ 251,825 $ - $ 251,825 Fair value of contingent consideration 1,800 - 1,800 Net assets acquired $ 253,625 $ - $ 253,625 As summarized in the table, there were adjustments totaling $13.5 $58.0 $75.0 $2.3 Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology, trade names, and customer relationships was based on management's forecasted cash inflows and outflows and using either a relief-from-royalty or a multi-period excess earnings method to calculate the fair value of assets purchased. The preliminary amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. Preliminary amortization expense related to trade names, and customer relationships is reflected in selling, general and administrative expenses in the Consolidated Statement of Earnings and Comprehensive Income. The preliminary amortization periods for intangible assets acquired in fiscal 2019 15 14 not

Note 5 - Fair Value Measurement

Note 5 - Fair Value Measurements	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]	Not e 5 . Fair Value Measurements: The Company’s financial instruments include cash and cash equivalents, available for sale investments, accounts receivable, accounts payable, contingent consideration obligations, derivative instruments, and long-term debt. Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three 1 2 not 3 one 3 may The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands): Total carrying value as of Fair Value Measurements Using Inputs Considered as March 31, 201 9 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 57,193 $ 57,193 $ - $ - Certificates of Deposit (2) 26,036 26,036 - - Total Assets $ 83,229 $ 83,229 $ - $ - Liabilities Contingent Consideration $ 5,600 $ - $ - $ 5,600 Derivative Instruments - Cash Flow Hedges 7,561 - 7,561 - Total Liabilities $ 13,161 $ - $ 7,561 $ 5,600 Total carrying value as of Fair Value Measurements Using Inputs Considered as June 30, 2018 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 54,286 $ 54,286 $ - $ - Certificates of Deposit (2) 5,478 5,478 - - Total Assets $ 59,764 $ 59,764 $ - $ - Liabilities Contingent Consideration $ - $ - $ - $ - Derivative Instruments - Cash Flow Hedges - - - - Total Liabilities $ - $ - $ - $ - ( 1 Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at March 31, 2019 June 30, 2018 $18.8 ( 2 Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one Fair value measurements of available for sale securities Our available for sale securities are measured at fair value using quoted market prices in active markets for identical assets and are therefore classified as Level 1 Fair value measurements of derivative instruments In October 2018, 6 $380 not nine March 31, 2019. 2 Fair value measurements of contingent consideration In connection with the ExosomeDx and Quad acquisitions the Company is required to make contingent consideration payments of up to $325.0 $51.0 $6.7 $1.8 $4.9 4. 3 The following table presents a reconciliation of the liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3 nine March 31, 2019 ( Quarter Ended Nine Months Ended March 31, 201 9 March 31, 201 9 Fair value at the beginning of period $ 6,000 $ - Purchase price contingent consideration (Note 4) - 6,700 Change in fair value of contingent consideration (400 ) (1,100 ) Payments - - Fair value at the end of period $ 5,600 $ 5,600 The use of different assumptions, applying different judgment to matters that inherently are subjective and changes in future market conditions could result in different estimates of fair value of our securities or contingent consideration, currently and in the future. If market conditions deteriorate, we may Fair value measurements of other financial instruments Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the Condensed Consolidated Balance Sheet approximate fair value because of the short-term nature of these items. Long-term debt – The carrying amounts reported in the Condensed Consolidated Balance Sheet for the amount drawn on our line-of-credit facility and borrowed under our term loan approximate fair value because our interest rate is variable and reflects current market rates.

Note 6 - Debt and Other Financi

Note 6 - Debt and Other Financing Arrangements	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 6 . Debt and Other Financing Arrangements: On August 1, 2018, $600.0 $200.0 $250.0 may 20 The Credit Agreement matures on August 1, 2023 August 1, 2018, $250.0 $330.0 March 31, 2019, $522.6

Note 7 - Supplemental Equity an

Note 7 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Comprehensive Income (Loss) Note [Text Block]	Note 7 . Supplemental Equity and Accumulated Other Comprehensive Income (loss): Consolidated Changes in Equity (amounts in thousands) Common Stock Additional Paid-in Retained Accumulated Other Comprehensive Shares Amount Capital Earnings Income(Loss) Total Balances at June 30, 2018 37,608 $ 376 $ 246,568 $ 876,931 $ (44,814 ) $ 1,079,061 Cumulative effect adjustments due to adoption of new accounting standards 24,780 (24,682 ) 98 Net earnings 17,403 17,403 Other comprehensive loss (1,136 ) (1,136 ) Share repurchases - Surrender and retirement of stock to exercise options - Common stock issued for exercise of options 166 2 15,609 15,611 Common stock issued for restricted stock awards 24 0 (1,909 ) (1,909 ) Cash dividends (12,066 ) (12,066 ) Stock-based compensation expense 11,327 11,327 Common stock issued to employee stock purchase plan 5 0 842 842 Employee stock purchase plan expense 238 238 Balances at September 30, 2018 37,803 $ 378 $ 274,584 $ 905,139 $ (70,632 ) $ 1,109,469 Net earnings 17,556 17,556 Other comprehensive loss (12,379 ) (12,379 ) Share repurchases (95 ) (1 ) (15,404 ) (15,404 ) Surrender and retirement of stock to exercise options - Common stock issued for exercise of options 24 0 2,408 2,408 Common stock issued for restricted stock awards 3 0 0 - Cash dividends (12,086 ) (12,086 ) Stock-based compensation expense 6,784 6,784 Common stock issued to employee stock purchase plan 0 0 - Employee stock purchase plan expense 77 77 Balances at December 31, 2018 37,735 $ 377 $ 283,854 $ 895,205 $ (83,011 ) $ 1,096,425 Net earnings 44,654 44,654 Other comprehensive income 3,378 3,378 Share repurchases - Surrender and retirement of stock to Exercise options - Common stock issued for exercise of Options 73 1 7,336 7,337 Common stock issued for restricted stock Awards 1 0 - Cash dividends (12,086 ) (12,086 ) Stock-based compensation expense 5,640 5,640 Common stock issued to employee stock Purchase plan 4 0 834 834 Employee stock purchase plan expense 84 84 Balances at March 31, 2019 37,813 $ 378 $ 297,748 $ 927,773 $ (79,633 ) $ 1,146,266 Common Stock Additional Paid-in Retained Accumulated Other Comprehensive Shares Amount Capital Earnings Income(Loss) Total Balances at June 30, 2017 37,356 $ 374 $ 199,161 $ 799,027 $ (48,935 ) $ 949,627 Net earnings 15,863 15,863 Other comprehensive loss (824 ) (824 ) Surrender and retirement of stock to exercise options 0 Common stock issued for exercise of options 33 0 3,051 3,051 Common stock issued for restricted stock awards 13 0 (227 ) (227 ) Cash dividends (11,958 ) (11,958 ) Stock-based compensation expense 3,718 3,718 Common stock issued to employee stock purchase plan 7 0 755 755 Employee stock purchase plan expense 77 77 Balances at September 30, 2017 37,409 $ 374 $ 206,762 $ 802,705 $ (49,759 ) $ 960,082 Net earnings 48,847 48,847 Other comprehensive loss (7,058 ) (7,058 ) Surrender and retirement of stock to exercise options - Common stock issued for exercise of options 38 1 2,892 2,893 Common stock issued for restricted stock awards 22 0 0 - Cash dividends (11,988 ) (11,988 ) Stock-based compensation expense 4,985 4,985 Common stock issued to employee stock purchase plan - - - Employee stock purchase plan expense 59 59 Balances at December 31, 2017 37,470 $ 375 $ 214,697 $ 839,564 $ (56,817 ) $ 997,819 Net earnings 19,738 19,738 Other Comprehensive Loss 40,956 40,956 Surrender and retirement of stock to Exercise options - Common stock issued for exercise of options 68 6,273 6,273 Common Stock issued for restricted stock awards - Cash dividends (11,992 ) (11,992 ) Stock-based compensation expenses 4,669 4,669 Common stock issued to employee stock purchase plan 7 752 752 Employee stock purchase plan expense 78 78 Balances at March 31, 2018 37,545 $ 375 $ 226,469 $ 847,310 $ (15,862 ) $ 1,058,292 Accumulated Other Comprehensive Income The components of other comprehensive income (loss) consist of changes in net unrealized gains (losses) on available for sale investments with readily determinable fair values in fiscal 2018, 2019. no nine March 31, 2019 2018. The accumulated balances related to each component of other comprehensive income (loss), net of tax, are summarized as follows (in thousands): Unrealized Gains Unrealized (Losses) on Foreign Gains Available- Currency (Losses) on for-Sale Translation Derivatives Investments Adjustments Instruments Total Beginning balance as of June 30, 2018 $ 24,682 $ (69,496 ) $ - $ (44,814 ) Cumulative effect adjustment for adoption for ASU 2018-02 (1) 2,371 - - 2,371 Cumulative effect adjustment for adoption for ASU 2016-01 (1) (27,053 ) - - (27,053 ) Other comprehensive income (loss), net of tax benefit of $1,792 on derivative instruments (2) - (4,368 ) (5,769 ) (10,137 ) Ending balance as of March 31, 2019 $ - $ (73,864 ) $ (5,769 ) $ (79,633 ) ( 1 ) 1 2016 01 2018 02. ( 2 October 31, 2019. $919 $5,769 12 March 31, 2019. Unrealized Gains Unrealized (Losses) on Foreign Gains Available- Currency (Losses) on for-Sale Translation Derivative Investments Adjustments Instruments Total Beginning balance as of June 30, 2017 $ 18,989 $ (67,924 ) $ - $ (48,935 ) Other comprehensive income (loss) 22,286 10,787 - 33,073 Ending balance as of March 31, 2018 $ 41,275 (57,137 ) $ - $ (15,862 )

Note 8 - Earnings Per Share

Note 8 - Earnings Per Share	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 8 . Earnings Per Share: The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts): Quarter Ended Nine Months Ended March 31, March 31, 201 9 201 8 201 9 201 8 Earnings per share – basic: Net income $ 44,654 $ 19,738 $ 79,612 $ 84,449 Income allocated to participating securities (35 ) (18 ) (66 ) (70 ) Income available to common shareholders $ 44,619 $ 19,720 $ 79,546 $ 84,379 Weighted-average shares outstanding – basic 37,772 37,503 37,745 37,450 Earnings per share – basic $ 1.18 $ 0.53 $ 2.11 $ 2.25 Earnings per share – diluted: Net income $ 44,654 $ 19,738 $ 79,612 $ 84,449 Income allocated to participating securities (35 ) (18 ) (66 ) (70 ) Income available to common shareholders $ 44,619 $ 19,720 $ 79,546 $ 84,379 Weighted-average shares outstanding – basic 37,772 37,503 37,745 37,450 Dilutive effect of stock options and restricted stock units 1,089 639 1,068 483 Weighted-average common shares outstanding – diluted 38,861 38,142 38,813 37,933 Earnings per share – diluted $ 1.15 $ 0.52 $ 2.05 $ 2.22 The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutiv e option shares excluded from the calculation was 1.3 1.1 March 31, 2019 2018, 1.3 1.6 nine March 31, 2019 2018,

Note 9 - Share-based Compensati

Note 9 - Share-based Compensation	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	Note 9. Share-based Compensation: During the nine March 31, 2019 2018, 0.9 1.1 $173.89 $120.34 $34.66 $21.98, nine March 31, 2019 2018, 56,403 65,924 $170.96 $128.30, nine March 31, 2019 2018, 14,877 20,106 $177.93 $125.05, Stock options for 263,995 139,602 $22.3 $6.3 nine March 31, 2019 2018, Stock-based compensation expense of $5.7 $4.7 March 31, 2019 2018, 24.2 million $13.6 nine March 31, 2019 2018, March 31, 2019, $32.1 2.1

Note 10 - Other Income (Expense

Note 10 - Other Income (Expense)	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Other Income and Other Expense Disclosure [Text Block]	Note 10 . Other Income / (Expense): The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows: Quarter Ended Nine Months March 31, March 31, 201 9 201 8 201 9 201 8 Interest expense $ (5,113 ) $ (2,560 ) (16,110 ) $ (7,135 ) Interest income 84 162 299 307 Impairment of Investment - (16,246 ) - (16,246 ) Other non-operating income (expense), net 10,816 542 1,585 (507 ) Total other income (expense) $ 5,787 $ (18,102 ) (14,226 ) $ (23,581 )

Note 11 - Income Taxes

Note 11 - Income Taxes	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 11 . Income Taxes: The Company’s effective income tax rate for the third 2019 2018 10.5% 21.0% 10.8% 21.2 first nine 2019 2018, third first nine 2019 third first nine 2018 The Company recognized total net benefits related to discrete tax items of $6.2 third $11.4 first nine 2019. $2.9 3.5 third first nine 2019, $1.1 $4.8 third first nine 2019, $2.2 nine March 31, 2019 The Company recognized total net benefits related to discrete tax items of $0.7 third $36.7 first nine 2018. $31.7 first nine 2018. $3.2 first nine 2018 not no March 31, 2018 On December 22, 2017, 35% 21%, one 118” 2018 05 Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin (SAB) No. 118, one During the quarter, the Company recorded a net discrete benefit of $2.9 may $5.5 The end of the measurement period allowed under ASU 2018 05 December 31, 2018. may

Note 12 - Segment Information

Note 12 - Segment Information	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 12. Segment Information: The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with acquisition accounting related to inventory, stock based compensation, amortization of acquisition-related intangible assets and other acquisition-related expenses. The Protein Sciences and Diagnostics and Genomics reportable segments both include consumables, instruments, services and royalty revenue. The following is financial information relating to the Company's reportable segments (in thousands): Quarter Ended Nine Months Ended March 31, March 31, 201 9 201 8 201 9 201 8 Net sales: Protein Sciences $ 137,935 $ 123,187 $ 399,787 $ 348,442 Diagnostics and Genomics 47,134 40,929 123,144 114,604 Intersegment (208 ) (143 ) (590 ) (307 ) Consolidated net sales $ 184,861 $ 163,973 $ 522,341 $ 462,739 Operating income: Protein Sciences $ 62,256 $ 53,813 $ 175,821 $ 150,240 Diagnostics and Genomics 3,579 9,649 5,061 22,816 Segment operating income $ 65,835 $ 63,462 $ 180,882 $ 173,056 Costs recognized on sale of acquired inventory (935 ) (1,431 ) (2,804 ) (2,013 ) Amortization of acquisition related intangible assets (14,400 ) (11,872 ) (43,678 ) (34,547 ) Acquisition related expenses - (1,312 ) (2,973 ) (23,994 ) Stock based compensation (5,725 ) (4,748 ) (24,151 ) (13,587 ) Corporate general, selling, and administrative expenses (685 ) (1,015 ) (3,821 ) (5,652 ) Consolidated operating income $ 44,090 $ 43,084 $ 103,455 $ 93,263

Note 13 - Subsequent Events

Note 13 - Subsequent Events	9 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	Note 13. Subsequent Events: None.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In May 2014, No. 2014 09, Revenue from Contracts with Customers 606 606 On July 1, 2018, 606 July 1, 2018 606, not 605, Revenue Recognition The Company recorded a net increase to beginning retained earnings of $98,000 July 1, 2018 606. 606 not nine March 31, 2019 not 2 606. In January 2016, No. 2016 01 Recognition and Measurement of Financial Assets and Financial Liabilities no 2016 01 July 1, 2018 $54.3 $35.4 $8.3 $27.1 2019. 2016 01, July 1, 2018 orded a gain in other (expense) income of $12.3 $2.9 nine March 31, 2019 2016 01 In February 2018, No. 2018 02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income 2017. December 15, 2018, July 1, 2019. 2018 02 July 1, 2018. $2.4 2018 02 2016 01 The following table presents a summary of cumulative effect adjustments to retained earnings due to the adoption of new accounting standards on July 1, 2018 Cumulative Effect Adjustments to Retained Earnings on July 1, 2018 Increase / (Decrease) Cumulative effect adjustment to retained earnings due to the adoption of the following new accounting standards: ASU 2014-09 $ 98 ASU 2016-01 27,053 ASU 2018-02 (2,371 ) Net cumulative effect adjustments to retained earnings on July 1, 2018 due to the adoption of new accounting standards $ 24,780 In January 2017, No. 2017 01, Clarifying the Definition of a Business July 1, 2018, In August 2017, No. 2017 - 12, Targeted Improvements to Accounting for Hedging Activities December 15, 2018, July 1, 2019. 2017 12 October 1, 2018, 5. not Pronouncements Issued But Not In February 2016, 2016 02, Leases (Topic 842 December 15, 2018, July 1, 2019. Leases (Topic 842 ASU No. 2018 10 ASU 2019 01 ASU 2018 11 not 2018 11 Leases (Topic 842 not In June 2016, 2016 13, Financial Instruments - Credit Losses (Topic 326 ), Measurement of Credit Losses on Financial Instruments December 15, 2019, July 1, 2020. may December 15, 2018. 2016 13 In August 2018, No. 2018 15, Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract not December 15, 2019, July 1, 2020 may first 2018 15

Note 1 - Basis of Presentatio_2

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Cumulative Effect Adjustments to Retained Earnings on July 1, 2018 Increase / (Decrease) Cumulative effect adjustment to retained earnings due to the adoption of the following new accounting standards: ASU 2014-09 $ 98 ASU 2016-01 27,053 ASU 2018-02 (2,371 ) Net cumulative effect adjustments to retained earnings on July 1, 2018 due to the adoption of new accounting standards $ 24,780

Note 2 - Revenue Recognition (T

Note 2 - Revenue Recognition (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Disaggregation of Revenue [Table Text Block]	Quarter Ended March 31 , Nine Months Ended March 31, 201 9 201 8 201 9 201 8 Consumables $ 153,783 $ 139,416 $ 429,340 385,164 Instruments 16,104 13,197 51,116 44,047 Services 9,565 8,362 27,027 25,400 Total product and services revenue, net 179,452 160,975 $ 507,483 454,611 Royalty revenues 5,409 2,998 14,858 8,128 Total revenues, net $ 184,861 $ 163,973 $ 522,341 462,739 Quarter Ended March 31, Nine Months Ended March 31, 201 9 201 8 201 9 201 8 United States $ 98,228 $ 86,447 $ 281,585 $ 246,857 EMEA, excluding United Kingdom 42,339 39,318 116,018 107,082 United Kingdom 10,737 9,164 26,703 24,276 APAC, excluding Greater China 14,943 13,107 39,990 36,439 Greater China 12,993 11,097 42,727 35,006 Rest of World 5,621 4,840 15,318 13,079 Total revenues, net $ 184,861 $ 163,973 $ 522,341 $ 462,739

Note 3 - Selected Balance She_2

Note 3 - Selected Balance Sheet Data (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 201 9 June 30, 2018 Raw materials $ 37,176 $ 30,956 Finished goods 56,663 54,692 Inventories, net $ 93,839 $ 85,648
Property, Plant and Equipment [Table Text Block]	March 31, June 30, 201 9 2018 Land $ 7,065 $ 7,065 Buildings and improvements 172,826 170,110 Machinery and equipment 117,105 107,625 Property and equipment, cost 296,996 284,800 Accumulated depreciation and amortization (151,677 ) (139,452 ) Property and equipment, net $ 145,319 $ 145,348
Schedule of Intangible Assets and Goodwill [Table Text Block]	March 31, June 30, 201 9 2018 Developed technology $ 422,039 $ 305,303 Trade names 147,340 89,608 Customer relationships 212,996 212,228 Patents 1,981 1,401 Intangible assets 784,356 608,540 Accumulated amortization (205,214 ) (162,208 ) Intangible assets, net $ 579,142 $ 446,332
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Beginning balance $ 446,332 Acquisitions 177,500 Other additions 558 Amortization expense (43,797 ) Currency translation (1,451 ) Ending balance $ 579,142
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	2019 (remainder) $ 14,868 2020 58,873 2021 58,518 2022 56,822 2023 54,942 Thereafter 335,119 Total $ 579,142
Schedule of Goodwill [Table Text Block]	Protein Sciences Diagnostics and Genomics Total Beginning balance $ 347,918 $ 249,972 $ 597,890 Acquisitions (Note 4) 13,582 110,066 123,648 Currency translation (1,821 ) (108 ) (1,930 ) Ending balance $ 359,679 $ 359,929 $ 719,608

Note 4 - Acquisitions (Tables)

Note 4 - Acquisitions (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Preliminary Allocation at Acquisition Date Adjustments to Fair Value Adjusted Preliminary Allocation at March 31, 201 9 Current assets, net of cash $ 36 $ - $ 36 Equipment and other long-term assets 284 - 284 Intangible assets: Developed technology 20,000 (7,800 ) 12,200 Goodwill 9,790 3,792 13,582 Total assets acquired 30,110 (4,008 ) 26,102 Liabilities 765 (469 ) 296 Deferred income taxes, net 3,741 (3,296 ) 445 Net assets acquired $ 25,604 $ (243 ) $ 25,361 Cash paid, net of cash acquired $ 20,404 $ 57 $ 20,461 Fair value of contingent consideration 5,200 (300 ) 4,900 Net assets acquired $ 25,604 $ (243 ) $ 25,361 Preliminary Allocation at Acquisition Date Adjustments to Fair Value Adjusted Preliminary Allocation at March 31, 201 9 Current assets, net of cash $ 5,118 $ (2,554 ) $ 2,564 Equipment and other long-term assets 2,212 - 2,212 Intangible assets: Developed technology 180,000 (75,000 ) 105,000 Trade Name - 58,000 58,000 Customer Relationships - 2,300 2,300 Goodwill 96,592 13,474 110,066 Total assets acquired 283,922 (3,780 ) 280,142 Liabilities 2,624 210 2,834 Deferred income taxes, net 27,673 (3,990 ) 23,683 Net assets acquired $ 253,625 $ - $ 253,625 Cash paid, net of cash acquired $ 251,825 $ - $ 251,825 Fair value of contingent consideration 1,800 - 1,800 Net assets acquired $ 253,625 $ - $ 253,625

Note 5 - Fair Value Measureme_2

Note 5 - Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Total carrying value as of Fair Value Measurements Using Inputs Considered as March 31, 201 9 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 57,193 $ 57,193 $ - $ - Certificates of Deposit (2) 26,036 26,036 - - Total Assets $ 83,229 $ 83,229 $ - $ - Liabilities Contingent Consideration $ 5,600 $ - $ - $ 5,600 Derivative Instruments - Cash Flow Hedges 7,561 - 7,561 - Total Liabilities $ 13,161 $ - $ 7,561 $ 5,600 Total carrying value as of Fair Value Measurements Using Inputs Considered as June 30, 2018 Level 1 Level 2 Level 3 Assets Equity securities (1) $ 54,286 $ 54,286 $ - $ - Certificates of Deposit (2) 5,478 5,478 - - Total Assets $ 59,764 $ 59,764 $ - $ - Liabilities Contingent Consideration $ - $ - $ - $ - Derivative Instruments - Cash Flow Hedges - - - - Total Liabilities $ - $ - $ - $ -
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Quarter Ended Nine Months Ended March 31, 201 9 March 31, 201 9 Fair value at the beginning of period $ 6,000 $ - Purchase price contingent consideration (Note 4) - 6,700 Change in fair value of contingent consideration (400 ) (1,100 ) Payments - - Fair value at the end of period $ 5,600 $ 5,600

Note 7 - Supplemental Equity _2

Note 7 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Consolidated Stockholders' Equity Statement [Table Text Block]	Common Stock Additional Paid-in Retained Accumulated Other Comprehensive Shares Amount Capital Earnings Income(Loss) Total Balances at June 30, 2018 37,608 $ 376 $ 246,568 $ 876,931 $ (44,814 ) $ 1,079,061 Cumulative effect adjustments due to adoption of new accounting standards 24,780 (24,682 ) 98 Net earnings 17,403 17,403 Other comprehensive loss (1,136 ) (1,136 ) Share repurchases - Surrender and retirement of stock to exercise options - Common stock issued for exercise of options 166 2 15,609 15,611 Common stock issued for restricted stock awards 24 0 (1,909 ) (1,909 ) Cash dividends (12,066 ) (12,066 ) Stock-based compensation expense 11,327 11,327 Common stock issued to employee stock purchase plan 5 0 842 842 Employee stock purchase plan expense 238 238 Balances at September 30, 2018 37,803 $ 378 $ 274,584 $ 905,139 $ (70,632 ) $ 1,109,469 Net earnings 17,556 17,556 Other comprehensive loss (12,379 ) (12,379 ) Share repurchases (95 ) (1 ) (15,404 ) (15,404 ) Surrender and retirement of stock to exercise options - Common stock issued for exercise of options 24 0 2,408 2,408 Common stock issued for restricted stock awards 3 0 0 - Cash dividends (12,086 ) (12,086 ) Stock-based compensation expense 6,784 6,784 Common stock issued to employee stock purchase plan 0 0 - Employee stock purchase plan expense 77 77 Balances at December 31, 2018 37,735 $ 377 $ 283,854 $ 895,205 $ (83,011 ) $ 1,096,425 Net earnings 44,654 44,654 Other comprehensive income 3,378 3,378 Share repurchases - Surrender and retirement of stock to Exercise options - Common stock issued for exercise of Options 73 1 7,336 7,337 Common stock issued for restricted stock Awards 1 0 - Cash dividends (12,086 ) (12,086 ) Stock-based compensation expense 5,640 5,640 Common stock issued to employee stock Purchase plan 4 0 834 834 Employee stock purchase plan expense 84 84 Balances at March 31, 2019 37,813 $ 378 $ 297,748 $ 927,773 $ (79,633 ) $ 1,146,266 Common Stock Additional Paid-in Retained Accumulated Other Comprehensive Shares Amount Capital Earnings Income(Loss) Total Balances at June 30, 2017 37,356 $ 374 $ 199,161 $ 799,027 $ (48,935 ) $ 949,627 Net earnings 15,863 15,863 Other comprehensive loss (824 ) (824 ) Surrender and retirement of stock to exercise options 0 Common stock issued for exercise of options 33 0 3,051 3,051 Common stock issued for restricted stock awards 13 0 (227 ) (227 ) Cash dividends (11,958 ) (11,958 ) Stock-based compensation expense 3,718 3,718 Common stock issued to employee stock purchase plan 7 0 755 755 Employee stock purchase plan expense 77 77 Balances at September 30, 2017 37,409 $ 374 $ 206,762 $ 802,705 $ (49,759 ) $ 960,082 Net earnings 48,847 48,847 Other comprehensive loss (7,058 ) (7,058 ) Surrender and retirement of stock to exercise options - Common stock issued for exercise of options 38 1 2,892 2,893 Common stock issued for restricted stock awards 22 0 0 - Cash dividends (11,988 ) (11,988 ) Stock-based compensation expense 4,985 4,985 Common stock issued to employee stock purchase plan - - - Employee stock purchase plan expense 59 59 Balances at December 31, 2017 37,470 $ 375 $ 214,697 $ 839,564 $ (56,817 ) $ 997,819 Net earnings 19,738 19,738 Other Comprehensive Loss 40,956 40,956 Surrender and retirement of stock to Exercise options - Common stock issued for exercise of options 68 6,273 6,273 Common Stock issued for restricted stock awards - Cash dividends (11,992 ) (11,992 ) Stock-based compensation expenses 4,669 4,669 Common stock issued to employee stock purchase plan 7 752 752 Employee stock purchase plan expense 78 78 Balances at March 31, 2018 37,545 $ 375 $ 226,469 $ 847,310 $ (15,862 ) $ 1,058,292
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Unrealized Gains Unrealized (Losses) on Foreign Gains Available- Currency (Losses) on for-Sale Translation Derivatives Investments Adjustments Instruments Total Beginning balance as of June 30, 2018 $ 24,682 $ (69,496 ) $ - $ (44,814 ) Cumulative effect adjustment for adoption for ASU 2018-02 (1) 2,371 - - 2,371 Cumulative effect adjustment for adoption for ASU 2016-01 (1) (27,053 ) - - (27,053 ) Other comprehensive income (loss), net of tax benefit of $1,792 on derivative instruments (2) - (4,368 ) (5,769 ) (10,137 ) Ending balance as of March 31, 2019 $ - $ (73,864 ) $ (5,769 ) $ (79,633 ) Unrealized Gains Unrealized (Losses) on Foreign Gains Available- Currency (Losses) on for-Sale Translation Derivative Investments Adjustments Instruments Total Beginning balance as of June 30, 2017 $ 18,989 $ (67,924 ) $ - $ (48,935 ) Other comprehensive income (loss) 22,286 10,787 - 33,073 Ending balance as of March 31, 2018 $ 41,275 (57,137 ) $ - $ (15,862 )

Note 8 - Earnings Per Share (Ta

Note 8 - Earnings Per Share (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Quarter Ended Nine Months Ended March 31, March 31, 201 9 201 8 201 9 201 8 Earnings per share – basic: Net income $ 44,654 $ 19,738 $ 79,612 $ 84,449 Income allocated to participating securities (35 ) (18 ) (66 ) (70 ) Income available to common shareholders $ 44,619 $ 19,720 $ 79,546 $ 84,379 Weighted-average shares outstanding – basic 37,772 37,503 37,745 37,450 Earnings per share – basic $ 1.18 $ 0.53 $ 2.11 $ 2.25 Earnings per share – diluted: Net income $ 44,654 $ 19,738 $ 79,612 $ 84,449 Income allocated to participating securities (35 ) (18 ) (66 ) (70 ) Income available to common shareholders $ 44,619 $ 19,720 $ 79,546 $ 84,379 Weighted-average shares outstanding – basic 37,772 37,503 37,745 37,450 Dilutive effect of stock options and restricted stock units 1,089 639 1,068 483 Weighted-average common shares outstanding – diluted 38,861 38,142 38,813 37,933 Earnings per share – diluted $ 1.15 $ 0.52 $ 2.05 $ 2.22

Note 10 - Other Income (Expen_2

Note 10 - Other Income (Expense) (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	Quarter Ended Nine Months March 31, March 31, 201 9 201 8 201 9 201 8 Interest expense $ (5,113 ) $ (2,560 ) (16,110 ) $ (7,135 ) Interest income 84 162 299 307 Impairment of Investment - (16,246 ) - (16,246 ) Other non-operating income (expense), net 10,816 542 1,585 (507 ) Total other income (expense) $ 5,787 $ (18,102 ) (14,226 ) $ (23,581 )

Note 12 - Segment Information (

Note 12 - Segment Information (Tables)	9 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Quarter Ended Nine Months Ended March 31, March 31, 201 9 201 8 201 9 201 8 Net sales: Protein Sciences $ 137,935 $ 123,187 $ 399,787 $ 348,442 Diagnostics and Genomics 47,134 40,929 123,144 114,604 Intersegment (208 ) (143 ) (590 ) (307 ) Consolidated net sales $ 184,861 $ 163,973 $ 522,341 $ 462,739 Operating income: Protein Sciences $ 62,256 $ 53,813 $ 175,821 $ 150,240 Diagnostics and Genomics 3,579 9,649 5,061 22,816 Segment operating income $ 65,835 $ 63,462 $ 180,882 $ 173,056 Costs recognized on sale of acquired inventory (935 ) (1,431 ) (2,804 ) (2,013 ) Amortization of acquisition related intangible assets (14,400 ) (11,872 ) (43,678 ) (34,547 ) Acquisition related expenses - (1,312 ) (2,973 ) (23,994 ) Stock based compensation (5,725 ) (4,748 ) (24,151 ) (13,587 ) Corporate general, selling, and administrative expenses (685 ) (1,015 ) (3,821 ) (5,652 ) Consolidated operating income $ 44,090 $ 43,084 $ 103,455 $ 93,263

Note 1 - Basis of Presentatio_3

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)	3 Months Ended	9 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Jul. 01, 2018USD ($)	Jun. 30, 2018USD ($)
Number of Operating Segments		5
Number of Reportable Segments		2
Retained Earnings (Accumulated Deficit), Ending Balance	$ 927,773,000	$ 927,773,000		$ 876,931,000
Available-for-sale Securities, Total				54,300,000
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax, Total				35,400,000
Deferred Tax Liabilities, Other Comprehensive Income				8,300,000
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total	(79,633,000)	(79,633,000)		$ (44,814,000)
Accounting Standards Update 2014-09 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance			$ 98,000
Accounting Standards Update 2016-01 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance			27,100,000
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total			(27,100,000)
Accounting Standards Update 2016-01 [Member] | Other Nonoperating Income (Expense) [Member]
Equity Securities, FV-NI, Gain (Loss), Total	$ 12,300,000	$ 2,900,000
Accounting Standards Update 2018-02 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance			(2,400,000)
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total			$ 2,400,000

Note 1 - Basis of Presentatio_4

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies - Cumulative Effect Adjustments to Retained Earnings (Details) - USD ($) $ in Thousands	Jul. 01, 2018	Jun. 30, 2018
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards		$ 98
Retained Earnings [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	$ 24,780	$ 24,780
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	98
Accounting Standards Update 2016-01 [Member] | Retained Earnings [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	27,053
Accounting Standards Update 2018-02 [Member] | Retained Earnings [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	$ (2,371)

Note 2 - Revenue Recognition (D

Note 2 - Revenue Recognition (Details Textual) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2019	Jun. 30, 2018
Contract with Customer, Liability, Total	$ 11.5	$ 11.5	$ 9.3
Contract with Customer, Liability, Revenue Recognized	$ 0.9	$ 6.5

Note 2 - Revenue Recognition -

Note 2 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Revenues, net	$ 184,861	$ 163,973	$ 522,341	$ 462,739
UNITED STATES
Revenues, net	98,228	86,447	281,585	246,857
EMEA, excluding U.K. [Member]
Revenues, net	42,339	39,318	116,018	107,082
UNITED KINGDOM
Revenues, net	10,737	9,164	26,703	24,276
APAC, excluding Greater China [Member]
Revenues, net	14,943	13,107	39,990	36,439
CHINA
Revenues, net	12,993	11,097	42,727	35,006
Rest of World [Member]
Revenues, net	5,621	4,840	15,318	13,079
Consumables [Member]
Revenues, net	153,783	139,416	429,340	385,164
Instruments [Member]
Revenues, net	16,104	13,197	51,116	44,047
Service [Member]
Revenues, net	9,565	8,362	27,027	25,400
Product and Services [Member]
Revenues, net	179,452	160,975	507,483	454,611
Royalty [Member]
Revenues, net	$ 5,409	$ 2,998	$ 14,858	$ 8,128

Note 3 - Selected Balance She_3

Note 3 - Selected Balance Sheet Data - Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Raw materials	$ 37,176	$ 30,956
Finished goods	56,663	54,692
Inventories, net	$ 93,839	$ 85,648

Note 3 - Selected Balance She_4

Note 3 - Selected Balance Sheet Data - Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Property and equipment, cost	$ 296,996	$ 284,800
Accumulated depreciation and amortization	(151,677)	(139,452)
Property and equipment, net	145,319	145,348
Land [Member]
Property and equipment, cost	7,065	7,065
Building and Building Improvements [Member]
Property and equipment, cost	172,826	170,110
Machinery and Equipment [Member]
Property and equipment, cost	$ 117,105	$ 107,625

Note 3 - Selected Balance She_5

Note 3 - Selected Balance Sheet Data - Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Intangible assets	$ 784,356	$ 608,540
Accumulated amortization	(205,214)	(162,208)
Intangible assets, net	579,142	446,332
Developed Technology Rights [Member]
Intangible assets	422,039	305,303
Trade Names [Member]
Intangible assets	147,340	89,608
Customer Relationships [Member]
Intangible assets	212,996	212,228
Patents [Member]
Intangible assets	$ 1,981	$ 1,401

Note 3 - Selected Balance She_6

Note 3 - Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2019USD ($)
Beginning balance	$ 446,332
Acquisitions	177,500
Other additions	558
Amortization expense	(43,797)
Currency translation	(1,451)
Ending balance	$ 579,142

Note 3 - Selected Balance She_7

Note 3 - Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Mar. 31, 2019USD ($)
2019 (remainder)	$ 14,868
2020	58,873
2021	58,518
2022	56,822
2023	54,942
Thereafter	335,119
Total	$ 579,142

Note 3 - Selected Balance She_8

Note 3 - Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Mar. 31, 2019USD ($)
Beginning balance	$ 597,890
Acquisitions (Note 4)	123,648
Currency translation	(1,930)
Ending balance	719,608
Protein Sciences [Member]
Beginning balance	347,918
Acquisitions (Note 4)	13,582
Currency translation	(1,821)
Ending balance	359,679
Diagnostics and Genomics [Member]
Beginning balance	249,972
Acquisitions (Note 4)	110,066
Currency translation	(108)
Ending balance	$ 359,929

Note 4 - Acquisitions (Details

Note 4 - Acquisitions (Details Textual) - USD ($) $ in Thousands	Aug. 01, 2018	Jul. 02, 2018	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Feb. 01, 2018	Jan. 02, 2018
Payments to Acquire Businesses, Net of Cash Acquired, Total				$ 272,286			$ 65,066
QT Holdings Corporation [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total		$ 20,404				$ 20,461
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		51,000	$ 51,000	51,000	$ 51,000	51,000
Goodwill, Purchase Accounting Adjustments					3,800	3,792
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		$ 20,000	12,200	12,200	12,200	12,200
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles						(7,800)
Atlanta Biologicals [Member]
Business Acquisition, Goodwill, Expected Tax Deductible Amount									$ 0
Exosome Diagnostics, Inc [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	$ 251,825		251,825
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	325,000		325,000	325,000	325,000	325,000
Business Acquisition, Goodwill, Expected Tax Deductible Amount	0
Goodwill, Purchase Accounting Adjustments			13,474
Exosome Diagnostics, Inc [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			58,000	58,000	58,000	58,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles			58,000
Exosome Diagnostics, Inc [Member] | Developed Technology [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	180,000		105,000	105,000	105,000	105,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles			(75,000)
Exosome Diagnostics, Inc [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			2,300	$ 2,300	2,300	2,300
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles			2,300
Finite-Lived Intangible Asset, Useful Life				14 years
Exosome Diagnostics, Inc [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life				15 years
Exosome Diagnostics, Inc [Member] | Calendar Year 2020 EBITA Between $45 Million and $58 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	250,000
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for A New Instrument Product Between $54 Million and $70 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	45,000
Exosome Diagnostics, Inc [Member] | Calendar Year 2022 EBITA for Remaining Business Between $150 Million and $190 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 30,000
Eurocell Diagnostics, SAS [Member]
Business Acquisition, Goodwill, Expected Tax Deductible Amount								$ 0
Goodwill, Purchase Accounting Adjustments			13,500
Eurocell Diagnostics, SAS [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			58,000	$ 58,000	58,000	58,000
Eurocell Diagnostics, SAS [Member] | Developed Technology [Member]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles			(75,000)
Eurocell Diagnostics, SAS [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 2,300	$ 2,300	$ 2,300	$ 2,300

Note 4 - Acquisitions - Prelimi

Note 4 - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Thousands	Aug. 01, 2018	Jul. 02, 2018	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Goodwill			$ 719,608	$ 719,608	$ 719,608	$ 719,608	$ 719,608		$ 597,890
Payments to Acquire Businesses, Net of Cash Acquired, Total					272,286			$ 65,066
QT Holdings Corporation [Member]
Current assets, net of cash		$ 36	36	36	36	36	36
Equipment and other long-term assets		284	284	284	284	284	284
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		20,000	12,200	12,200	12,200	12,200	12,200
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles							(7,800)
Goodwill		9,790	13,582	13,582	13,582	13,582	13,582
Goodwill, Purchase Accounting Adjustments						3,800	3,792
Total assets acquired		30,110	26,102	26,102	26,102	26,102	26,102
Total assets acquired, adjustments							(4,008)
Liabilities		765	296	296	296	296	296
Liabilities							(469)
Deferred income taxes, net		3,741	445	445	445	445	445
Deferred income taxes, net, adjustments							(3,296)
Net assets acquired		25,604	25,361	25,361	25,361	25,361	25,361
Net assets acquired, adjustments							(243)
Payments to Acquire Businesses, Net of Cash Acquired, Total		20,404					20,461
Cash paid, net of cash acquired, adjustments							57
Fair value of contingent consideration		5,200					4,900
Fair value of contingent consideration, adjustments							(300)
Net assets acquired		25,604					25,361
Net assets acquired		$ 25,604	25,361	25,361	25,361	25,361	25,361
Exosome Diagnostics, Inc [Member]
Current assets, net of cash	$ 5,118		2,564	2,564	2,564	2,564	2,564
Equipment and other long-term assets	2,212		2,212	2,212	2,212	2,212	2,212
Goodwill	96,592		110,066	110,066	110,066	110,066	110,066
Goodwill, Purchase Accounting Adjustments				13,474
Total assets acquired	283,922		280,142	280,142	280,142	280,142	280,142
Liabilities	2,624		2,834	2,834	2,834	2,834	2,834
Liabilities				210
Deferred income taxes, net	27,673		23,683	23,683	23,683	23,683	23,683
Deferred income taxes, net, adjustments				(3,990)
Net assets acquired	253,625		253,625	253,625	253,625	253,625	253,625
Payments to Acquire Businesses, Net of Cash Acquired, Total	251,825			251,825
Fair value of contingent consideration	1,800			1,800
Net assets acquired	253,625			253,625
Current assets, net of cash, adjustment			(2,554)
Total assets acquired, adjustment				(3,780)
Net assets acquired	253,625		253,625	253,625	253,625	253,625	253,625
Exosome Diagnostics, Inc [Member] | Developed Technology [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	180,000		105,000	105,000	105,000	105,000	105,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles				(75,000)
Exosome Diagnostics, Inc [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			58,000	58,000	58,000	58,000	58,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles				58,000
Exosome Diagnostics, Inc [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			$ 2,300	2,300	$ 2,300	$ 2,300	$ 2,300
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles				$ 2,300

Note 5 - Fair Value Measureme_3

Note 5 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2019	Oct. 31, 2018	Aug. 01, 2018	Jul. 02, 2018	Jun. 30, 2018
Business Combination, Liabilities Arising from Contingencies, Amount Recognized					$ 6,700
Exosome Diagnostics, Inc [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 325,000		$ 325,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized					1,800
QT Holdings Corporation [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	51,000			$ 51,000
Business Combination, Liabilities Arising from Contingencies, Amount Recognized					4,900
Embedded Derivative Financial Instruments [Member] | Cash Flow Hedging [Member]
Derivative, Notional Amount		$ 380,000
CCXI [Member]
Investments, Total	$ 18,800				$ 18,800

Note 5 - Fair Value Measureme_4

Note 5 - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands		Mar. 31, 2019	Jun. 30, 2018
Total Assets		$ 83,229	$ 59,764
Contingent Consideration		5,600
Derivative Instruments - Cash Flow Hedges		7,561
Total Liabilities		13,161
Fair Value, Inputs, Level 1 [Member]
Total Assets		83,229	59,764
Contingent Consideration
Derivative Instruments - Cash Flow Hedges
Total Liabilities
Fair Value, Inputs, Level 2 [Member]
Total Assets
Contingent Consideration
Derivative Instruments - Cash Flow Hedges		7,561
Total Liabilities		7,561
Fair Value, Inputs, Level 3 [Member]
Total Assets
Contingent Consideration		5,600
Derivative Instruments - Cash Flow Hedges
Total Liabilities		5,600
Equity Securities [Member]
Investments, Fair Value Disclosure	[1]	57,193	54,286
Equity Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[1]	57,193	54,286
Equity Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[1]
Equity Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[1]
Certificates of Deposit [Member]
Investments, Fair Value Disclosure	[2]	26,036	5,478
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]
Investments, Fair Value Disclosure	[2]	26,036	5,478
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
Investments, Fair Value Disclosure	[2]
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]
Investments, Fair Value Disclosure	[2]
[1]	Included in available-for-sale investments on the balance sheet. The cost basis in the Company's investment in CCXI at March 31, 2019 and June 30, 2018 was $18.8 million.
[2]	Included in available-for-sale investments on the balance sheet. The certificate of deposits have contractual maturity dates within one year.

Note 5 - Fair Value Measureme_5

Note 5 - Fair Value Measurements - Liability Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Details) - Contingent Consideration [Member] - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2019
Fair value at the beginning of period	$ 6
Purchase price contingent consideration (Note 4)		6.7
Change in fair value of contingent consideration	(0.4)	(1.1)
Payments
Fair value at the end of period	$ 5.6	$ 5.6

Note 6 - Debt and Other Finan_2

Note 6 - Debt and Other Financing Arrangements (Details Textual) - USD ($) $ in Thousands	Aug. 01, 2018	Mar. 31, 2019	Mar. 31, 2018
Proceeds from Long-term Lines of Credit		$ 580,000	$ 55,000
Credit Agreement [Member]
Long-term Debt, Total		$ 522,600
Credit Agreement [Member] | Term Loan [Member]
Debt Instrument, Face Amount	$ 250,000
Proceeds from Issuance of Long-term Debt, Total	250,000
Revolving Credit Facility [Member] | Credit Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity	600,000
Line of Credit Facility, Additional Borrowing Capacity	$ 200,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.20%
Proceeds from Long-term Lines of Credit	$ 330,000

Note 7 - Supplemental Equity _3

Note 7 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Details Textual) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent	$ 0	$ 0
Stockholders' Equity Attributable to Parent, Ending Balance	1,146,266	1,058,292		$ 1,096,425	$ 1,109,469	$ 1,079,061	$ 997,819	$ 960,082	$ 949,627
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]
Stockholders' Equity Attributable to Parent, Ending Balance	$ (5,769)
Forecast [Member]
Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent			$ 919

Note 7 - Supplemental Equity _4

Note 7 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Consolidated Changes in Equity (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Mar. 31, 2019	Mar. 31, 2018
Balance (in shares)			37,607,500				37,607,500
Balance	$ 1,096,425	$ 1,109,469	$ 1,079,061	$ 997,819	$ 960,082	$ 949,627	$ 1,079,061	$ 949,627
Cumulative effect adjustments due to adoption of new accounting standards			98				98
Net earnings	44,654	17,556	17,403	19,738	48,847	15,863	79,612	84,449
Other comprehensive income (loss)	3,378	(12,379)	(1,136)	40,956	(7,058)	(824)	$ (10,137)	$ 33,073
Share repurchases		(15,404)
Surrender and retirement of stock to exercise options						0
Common stock issued for exercise of options (in shares)							263,995	139,602
Common stock issued for exercise of options	7,337	2,408	15,611	6,273	2,893	3,051
Common stock issued for restricted stock awards			(1,909)			(227)
Cash dividends	(12,086)	(12,086)	(12,066)	(11,992)	(11,988)	(11,958)
Stock-based compensation expense	5,640	6,784	11,327	4,669	4,985	3,718
Common stock issued to employee stock purchase plan	834		842	752		755
Employee stock purchase plan expense	$ 84	77	238	78	59	77
Balance (in shares)	37,813,367						37,813,367
Balance	$ 1,146,266	$ 1,096,425	$ 1,109,469	$ 1,058,292	$ 997,819	$ 960,082	$ 1,146,266	$ 1,058,292
Common Stock [Member]
Balance (in shares)	37,735,000	37,803,000	37,608,000	37,470,000	37,409,000	37,356,000	37,608,000	37,356,000
Balance	$ 377	$ 378	$ 376	$ 375	$ 374	$ 374	$ 376	$ 374
Cumulative effect adjustments due to adoption of new accounting standards
Net earnings
Other comprehensive income (loss)
Share repurchases		(1)
Surrender and retirement of stock to exercise options
Common stock issued for exercise of options (in shares)	73,000	24,000	166,000	68,000	38,000	33,000
Common stock issued for exercise of options	$ 1	$ 0	$ 2		$ 1	$ 0
Common stock issued for restricted stock awards (in shares)	1,000	3,000	24,000		22,000	13,000
Common stock issued for restricted stock awards	$ 0	$ 0	$ 0		$ 0	$ 0
Cash dividends
Stock-based compensation expense
Common stock issued to employee stock purchase plan (in shares)	4,000	0	5,000	7,000		7,000
Common stock issued to employee stock purchase plan	$ 0	$ 0	$ 0			$ 0
Employee stock purchase plan expense
Share repurchases (in shares)		(95,000)
Balance (in shares)	37,813,000	37,735,000	37,803,000	37,545,000	37,470,000	37,409,000	37,813,000	37,545,000
Balance	$ 378	$ 377	$ 378	$ 375	$ 375	$ 374	$ 378	$ 375
Additional Paid-in Capital [Member]
Balance	283,854	274,584	246,568	214,697	206,762	199,161	246,568	199,161
Cumulative effect adjustments due to adoption of new accounting standards
Net earnings
Other comprehensive income (loss)
Share repurchases
Surrender and retirement of stock to exercise options
Common stock issued for exercise of options	7,336	2,408	15,609	6,273	2,892	3,051
Common stock issued for restricted stock awards
Cash dividends
Stock-based compensation expense	5,640	6,784	11,327	4,669	4,985	3,718
Common stock issued to employee stock purchase plan	834		842	752		755
Employee stock purchase plan expense	84	77	238	78	59	77
Balance	297,748	283,854	274,584	226,469	214,697	206,762	297,748	226,469
Retained Earnings [Member]
Balance	895,205	905,139	876,931	839,564	802,705	799,027	876,931	799,027
Cumulative effect adjustments due to adoption of new accounting standards			24,780				24,780
Net earnings	44,654	17,556	17,403	19,738	48,847	15,863
Other comprehensive income (loss)
Share repurchases		(15,404)
Surrender and retirement of stock to exercise options
Common stock issued for exercise of options
Common stock issued for restricted stock awards		0	(1,909)		0	(227)
Cash dividends	(12,086)	(12,086)	(12,066)	(11,992)	(11,988)	(11,958)
Stock-based compensation expense
Common stock issued to employee stock purchase plan
Employee stock purchase plan expense
Balance	927,773	895,205	905,139	847,310	839,564	802,705	927,773	847,310
AOCI Attributable to Parent [Member]
Balance	(83,011)	(70,632)	(44,814)	(56,817)	(49,759)	(48,935)	(44,814)	(48,935)
Cumulative effect adjustments due to adoption of new accounting standards			(24,682)				(24,682)
Net earnings
Other comprehensive income (loss)	3,378	(12,379)	(1,136)	40,956	(7,058)	(824)
Share repurchases
Surrender and retirement of stock to exercise options
Common stock issued for exercise of options
Common stock issued for restricted stock awards
Cash dividends
Stock-based compensation expense
Common stock issued to employee stock purchase plan
Employee stock purchase plan expense
Balance	$ (79,633)	$ (83,011)	$ (70,632)	$ (15,862)	$ (56,817)	$ (49,759)	$ (79,633)	$ (15,862)

Note 7 - Supplemental Equity _5

Note 7 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($) $ in Thousands		9 Months Ended
		Mar. 31, 2019		Mar. 31, 2018	Jun. 30, 2018
Balance		$ 1,079,061		$ 949,627
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards					$ 98
Balance		1,146,266		1,058,292
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]
Balance		24,682		18,989
Other comprehensive income (loss)			[1]	22,286
Balance				41,275
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Accounting Standards Update 2018-02 [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	[2]	2,371
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Accounting Standards Update 2016-01 [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	[2]	(27,053)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance		(69,496)		(67,924)
Other comprehensive income (loss)		(4,368)	[1]	10,787
Balance		(73,864)		(57,137)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	[2]
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | Accounting Standards Update 2016-01 [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	[2]
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]
Balance
Other comprehensive income (loss)		(5,769)	[1]
Balance		(5,769)
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member] | Accounting Standards Update 2018-02 [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	[2]
Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member] | Accounting Standards Update 2016-01 [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	[2]
AOCI Attributable to Parent [Member]
Balance		(44,814)		(48,935)
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards					$ (24,682)
Other comprehensive income (loss)		(10,137)	[1]	33,073
Balance		(79,633)		$ (15,862)
AOCI Attributable to Parent [Member] | Accounting Standards Update 2018-02 [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	[2]	2,371
AOCI Attributable to Parent [Member] | Accounting Standards Update 2016-01 [Member]
Net cumulative effect adjustments to Retained earnings on July 1, 2018 due to the adoption of new accounting standards	[2]	$ (27,053)
[1]	The gain (loss) on the forward starting interest rate swap will be reclassified into earnings beginning October 31, 2019. Approximately ($919) of the ($5,769) will be reclassified into earnings in the 12 months subsequent to March 31, 2019.
[2]	See Note 1 for further information related to the adoption of ASU 2016-01 and 2018-02.

Note 7 - Supplemental Equity _6

Note 7 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) (Parentheticals) $ in Thousands	9 Months Ended
	Mar. 31, 2019USD ($)
Tax benefit on derivative instruments	$ 1,792

Note 8 - Earnings Per Share (De

Note 8 - Earnings Per Share (Details Textual) - shares shares in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1.3	1.1	1.3	1.6

Note 8 - Earnings Per Share - S

Note 8 - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Mar. 31, 2019	Mar. 31, 2018
Net earnings	$ 44,654	$ 17,556	$ 17,403	$ 19,738	$ 48,847	$ 15,863	$ 79,612	$ 84,449
Income allocated to participating securities	(35)			(18)			(66)	(70)
Income available to common shareholders	$ 44,619			$ 19,720			$ 79,546	$ 84,379
Basic (in shares)	37,772			37,503			37,745	37,450
Basic (in dollars per share)	$ 1.18			$ 0.53			$ 2.11	$ 2.25
Net income	$ 44,654	$ 17,556	$ 17,403	$ 19,738	$ 48,847	$ 15,863	$ 79,612	$ 84,449
Income available to common shareholders	$ 44,619			$ 19,720			$ 79,546	$ 84,379
Dilutive effect of stock options and restricted stock units (in shares)	1,089			639			1,068	483
Weighted-average common shares outstanding – diluted (in shares)	38,861			38,142			38,813	37,933
Diluted (in dollars per share)	$ 1.15			$ 0.52			$ 2.05	$ 2.22

Note 9 - Share-based Compensa_2

Note 9 - Share-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			900,000	1,100,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 173.89	$ 120.34
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 34.66	$ 21.98
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			263,995	139,602
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value			$ 22.3	$ 6.3
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 32.1		$ 32.1
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition			2 years 36 days
Selling, General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expense	$ 5.7	$ 4.7	$ 24.2	$ 13.6
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			56,403	65,924
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 170.96	$ 128.30
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period			14,877	20,106
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 177.93	$ 125.05

Note 10 - Other Income (Expen_3

Note 10 - Other Income (Expense) - Schedule of Components of Other Income (Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Interest expense	$ (5,113)	$ (2,560)	$ (16,110)	$ (7,135)
Interest income	84	162	299	307
Impairment of Investment		(16,246)		(16,226)
Other non-operating income (expense), net	10,816	542	1,585	(507)
Total other income (expense)	$ 5,787	$ (18,102)	$ (14,226)	$ (23,581)

Note 11 - Income Taxes (Details

Note 11 - Income Taxes (Details Textual) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Effective Income Tax Rate Reconciliation, Percent, Total	10.50%	21.00%	10.80%	(21.20%)
Income Tax Expense (Benefit), Discrete Tax Items	$ (6.2)	$ (0.7)	$ (11.4)	$ (36.7)
Income Tax Expense (Benefit), Continuing Operations, Adjustments, New Legislation	(2.9)		(3.5)	(31.7)
Excess Tax Benefit from Share-based Compensation, Operating Activities	1.1		4.8
Income Tax Expense (Benefit) Discrete Tax Items State Apportionments	(2.2)		(2.2)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Revaluation of Contingent Consideration				$ 3.2
Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount	2.9
Additional Tax Expense That May be Recognized	$ 5.5		$ 5.5

Note 12 - Segment Information -

Note 12 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Net sales	$ 184,861	$ 163,973	$ 522,341	$ 462,739
Operating income	44,090	43,084	103,455	93,263
Costs recognized on sale of acquired inventory			(2,804)	(2,013)
Amortization of acquisition related intangible assets			(43,797)
Corporate general, selling, and administrative expenses	(64,968)	(53,285)	(195,622)	(175,349)
Operating Segments [Member]
Operating income	65,835	63,462	180,882	173,056
Operating Segments [Member] | Protein Sciences [Member]
Net sales	137,935	123,187	399,787	348,442
Operating income	62,256	53,813	175,821	150,240
Operating Segments [Member] | Diagnostics and Genomics [Member]
Net sales	47,134	40,929	123,144	114,604
Operating income	3,579	9,649	5,061	22,816
Intersegment Eliminations [Member]
Net sales	(208)	(143)	(590)	(307)
Segment Reconciling Items [Member]
Costs recognized on sale of acquired inventory	(935)	(1,431)	(2,804)	(2,013)
Amortization of acquisition related intangible assets	(14,400)	(11,872)	(43,678)	(34,547)
Acquisition related expenses		(1,312)	(2,973)	(23,994)
Stock based compensation	(5,725)	(4,748)	(24,151)	(13,587)
Corporate, Non-Segment [Member]
Corporate general, selling, and administrative expenses	$ (685)	$ (1,015)	$ (3,821)	$ (5,652)